Drug Trial Radar · NCT01967225
Safety and Efficacy of BAY1192631 in Japanese Patients With Methicillin-resistant Staphylococcus Aureus (MRSA) Infections
Last checked: Nov 20, 2026Latest source record: Oct 4, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
125
Actual
Start
Nov 23, 2013
Primary completion
Oct 28, 2016
Study completion Oct 28, 2016
Sponsor
- Lead sponsor
- BayerBayer (BAYRY)
- Sponsor type
- Industry
- First posted
- Oct 22, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this study is to see the efficacy and safety of BAY1192631 in Japanese patients with methicillin-resistant staphylococcus aureus (MRSA) (skin and soft tissue infections (SSTI) and SSTI-related bacteremia).
Conditions
- Skin Diseases, Infectious
Interventions
Tedizolid Phosphate (Sivextro, BAY1192631)Drug
BAY1192631 solution or tablet 200 mg, once daily, Intravenous (IV) or By Mouth (PO) for 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
LinezolidDrug
Linezolid solution or tablet 600 mg, twice daily, every 12 ±3 hours, Intravenous (IV) or By mouth (PO) 7-14 days for skin and soft tissue infections (SSTI) or 7-21 days for bacteremia.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinical Response at Test of Cure (TOC)Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia
- Microbiological Response at Test of Cure (TOC)Time frame: 7-14 days after the end of treatment (EOT) for skin and soft tissue infections (SSTI) and 4-6 weeks after EOT for bacteremia
Locations
46 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Fukuoka, Japan
Site not named
Gifu, Japan
Site not named
Kochi, Japan
Site not named
Kumamoto, Japan
Site not named
Nagasaki, Japan
Site not named
Osaka, Japan
Site not named
Shizuoka, Japan
Site not named
Shizuoka, Japan
Site not named
Toyama, Japan
Site not named
Nagakute, Aichi-ken, Japan
Site not named
Nagoya, Aichi-ken, Japan
Site not named
Nagoya, Aichi-ken, Japan
Site not named
Toyoake, Aichi-ken, Japan
Site not named
Yoshida, Fukui, Japan
Site not named
Kasuga, Fukuoka, Japan
Site not named
Kitakyushu, Fukuoka, Japan
Site not named
Miyako-gun, Fukuoka, Japan
Site not named
Sapporo, Hokkaido, Japan
Site not named
Sapporo, Hokkaido, Japan
Site not named
Amagasaki, Hyōgo, Japan
Site not named
Kobe, Hyōgo, Japan
Site not named
Inashiki-gun, Ibaraki, Japan
Site not named
Tsukuba, Ibaraki, Japan
Site not named
Kamakura, Kanagawa, Japan
Site not named
Sagamihara, Kanagawa, Japan
Site not named
Yokohama, Kanagawa, Japan
Site not named
Kōshi, Kumamoto, Japan
Site not named
Tsu, Mie-ken, Japan
Site not named
Sendai, Miyagi, Japan
Site not named
Nakagami-gun, Okinawa, Japan
Site not named
Shimajiri, Okinawa, Japan
Site not named
Hamamatsu, Shizuoka, Japan
Site not named
Iwata, Shizuoka, Japan
Site not named
Numazu, Shizuoka, Japan
Site not named
Meguro-ku, Tokyo, Japan
Site not named
Musashimurayama, Tokyo, Japan
Site not named
Ōta-ku, Tokyo, Japan
Site not named
Ōta-ku, Tokyo, Japan
Site not named
Ōta-ku, Tokyo, Japan
Site not named
Setagaya-ku, Tokyo, Japan
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.